Lazaro Delgado, MD
Nephrology · Kissimmee, FLNPI 1972579779
Payments from drug & device makers
Across 413 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Vifor Pharma, Inc.$963
- Otsuka America Pharmaceutical, Inc.$747
- Bayer$691
- Novartis$627
- Mallinckrodt Hospital Products Inc.$612
- plus $4K from 28 others
What the payments were for
- Food & beverage$8,55695%
- Education$4545%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 56 | $1,199 |
| Vifor Pharma, Inc. | 52 | $963 |
| Otsuka America Pharmaceutical, Inc. | 32 | $747 |
| Bayer | 27 | $691 |
| Novartis | 18 | $627 |
| Mallinckrodt Hospital Products Inc. | 31 | $612 |
| Amgen(2 entities) | 25 | $476 |
| Aurinia Pharma U.S., Inc. | 13 | $332 |
| Boehringer Ingelheim | 13 | $327 |
| Akebia Therapeutics Inc | 12 | $289 |
| GSK | 15 | $279 |
| Calliditas Therapeutics US Inc. | 13 | $266 |
| OPKO Pharmaceuticals, LLC | 14 | $264 |
| Fresenius USA Marketing, Inc. | 11 | $217 |
| ANI Pharmaceuticals, Inc. | 10 | $216 |
| Ardelyx, Inc. | 9 | $191 |
| Travere Therapeutics, Inc. | 10 | $181 |
| Mallinckrodt Enterprises LLC | 9 | $178 |
| Novo Nordisk | 7 | $136 |
| Baxter Healthcare | 5 | $128 |
| Vantive US Healthcare LLC | 4 | $116 |
| Renalytix AI, Inc. | 5 | $113 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $64 |
| Scpharmaceuticals Inc. | 2 | $59 |
| Lilly USA, LLC | 3 | $57 |
| Kyowa Kirin, Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Apellis Pharmaceuticals, Inc. | 2 | $43 |
| Shire North American Group Inc | 2 | $39 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Amicus Therapeutics, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $16 |
| Cormedix Inc. | 1 | $14 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,010 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 364 | $399,746 |
| JardianceEmpagliflozin | 153 | $181,283 |
| JanuviaSitagliptin Phosphate | 69 | $50,493 |
| KerendiaFinerenone | 30 | $44,813 |
| EntrestoSacubitril/Valsartan | 21 | $25,983 |
| ProcritEpoetin Alfa | 14 | $11,889 |
| DapagliflozinDapagliflozin Propanediol | 20 | $9,471 |
| Olmesartan Medoxomil | 356 | $8,069 |
| ProsolParenteral Amino Acid 20% No.1 | 18 | $4,714 |
| Torsemide | 130 | $3,034 |
| Losartan Potassium | 278 | $2,936 |
| Carvedilol | 364 | $2,887 |
| Chlorthalidone | 218 | $2,734 |
| Febuxostat | 25 | $2,361 |
| Hydralazine Hcl | 138 | $2,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,199 | $399,746364 claims |
| Boehringer IngelheimJardiance | $327 | $181,283153 claims |
| BayerKerendia | $691 | $44,81330 claims |
| NovartisEntresto | $627 | $25,98321 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $216 | $93642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 756 nephrology providers in Florida.
Other nephrology in Kissimmee
- Jorge LarranagaKissimmee$825K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.